Opportunity Information: Apply for PAR 18 941
The Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional) funding opportunity (NIH, PAR 18-941; CFDA 93.242) supports early-stage, high-impact research aimed at building the next generation of brain stimulation technologies for treating mental health disorders. The core intent is device development rather than basic science alone, with an emphasis on advancing what brain stimulation can do in terms of how precisely, how deeply, and how adaptively it can modulate neural circuits relevant to psychiatric symptoms. The mechanism is an R21, which is typically used for exploratory, proof-of-concept work where strong innovation and feasibility are central.
The FOA invites two main types of projects. First, applicants may propose entirely novel brain stimulation devices that go beyond conventional electrical or magnetic approaches, especially those capable of higher spatiotemporal precision, multi-focal stimulation (targeting more than one brain region or network node), and closed-loop operation (where sensing and stimulation are integrated so the device can adjust stimulation based on measured neural or behavioral signals). Second, applicants may propose substantial enhancements to existing brain stimulation devices that are already FDA-approved or FDA-cleared, but only if the improvements are meaningful and enable new performance or clinical capabilities. The announcement is explicit that incremental tweaks, such as minor software updates or small iterative modifications, are not considered responsive; the expectation is a clear step forward in capability.
In practical terms, proposals should focus on major gains in one or more of the following: spatial resolution (more precise targeting), depth of delivery (reaching relevant structures more effectively), and overall precision (better control over stimulation parameters and their effects). Projects that add genuinely new functional capabilities, such as robust closed-loop control, multi-site coordination, or improved targeting that changes the clinical potential of a device, align well with the stated priorities. Because this is framed around mental health applications, applicants should be able to explain how the device capabilities connect to psychiatric treatment needs, including plausible targets, biomarkers, or circuit-level hypotheses that justify the engineering direction.
The FOA also signals that successful applications should come from multi-disciplinary teams. NIH is looking for groups that can cover the full pipeline needed for device development: systems neuroscience to define relevant circuits and signals, engineering to design and build the hardware/software, clinical expertise to ensure real-world relevance and eventual clinical integration, and regulatory affairs expertise to anticipate requirements for safety, testing, and potential future FDA pathways. The inclusion of regulatory competence is a notable emphasis, since device projects often stall when regulatory planning is not built in early.
The funding instrument is a discretionary NIH grant, and the FOA is labeled "Clinical Trial Optional," meaning applicants may propose studies that do or do not involve clinical trials, depending on what is appropriate for the stage of development. The opportunity is broadly open to a wide range of eligible applicants, including state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (including small businesses); and other organizations. It also explicitly highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations) and regional organizations, underscoring an intent to encourage broad participation.
Administratively, the agency is the National Institutes of Health, and the original posting information indicates a creation date of 2018-09-27 and an original closing date of 2021-09-07, with the award ceiling and expected awards not specified in the provided source. Overall, the opportunity is best understood as NIH support for ambitious, prototype-to-demonstration level work that can materially change the capabilities of neuromodulation for mental health, particularly through novel modalities and closed-loop, multi-target precision approaches, rather than minor iterative updates to existing tools.Apply for PAR 18 941
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2018-09-27.
- Applicants must submit their applications by 2021-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is the NIH funding announcement titled Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional) (PAR 18-941; CFDA 93.242). It supports early-stage, high-impact work to develop next-generation brain stimulation technologies intended for mental health applications.
What is the main goal of the program?
The core intent is device development rather than basic science alone. The emphasis is on advancing what brain stimulation can do, especially improvements in:
- Precision (better control over stimulation parameters and effects)
- Spatial resolution (more precise targeting of neural circuits)
- Depth of delivery (reaching relevant brain structures more effectively)
- Adaptive capability (including closed-loop operation that adjusts based on measured signals)
What does the R21 mechanism mean for applicants?
The mechanism is an R21, typically used for exploratory and proof-of-concept efforts. Applications are expected to emphasize innovation and feasibility, consistent with early-stage development and demonstration work.
Are clinical trials required?
No. The FOA is labeled Clinical Trial Optional. Applicants may propose projects that include a clinical trial or projects that do not, depending on what fits the stage of the device development.
What kinds of projects are invited?
The FOA describes two main project types:
- Entirely novel brain stimulation devices that go beyond conventional electrical or magnetic approaches, especially devices with higher spatiotemporal precision, multi-focal stimulation, and/or closed-loop operation.
- Substantial enhancements to existing FDA-approved or FDA-cleared devices, but only when the improvements are meaningful and enable new performance or new clinical capabilities.
What is meant by "device development" rather than basic science?
While scientific rationale matters, the FOA is oriented toward building or significantly advancing hardware/software systems for neuromodulation. The expectation is that the work materially moves a device concept forward (prototype-to-demonstration style progress), rather than focusing only on generating basic biological knowledge without a clear device-development deliverable.
What does NIH consider "responsive" versus "not responsive" improvements?
The announcement is explicit that incremental tweaks are not responsive. Examples given include minor software updates or small iterative modifications. To be responsive, improvements to existing devices should represent a clear step forward in capability, enabling new performance or clinically meaningful functionality.
What technical capabilities does NIH emphasize?
The FOA highlights major gains in one or more of these areas:
- Spatial resolution (more precise targeting)
- Depth of delivery (better access to relevant structures)
- Overall precision (better control and predictability of effects)
It also strongly aligns with devices that add new functional capabilities such as closed-loop control (integrated sensing and stimulation) and multi-site coordination (targeting more than one brain region or network node).
What is multi-focal or multi-site stimulation in this context?
Multi-focal (or multi-site) stimulation refers to approaches that can stimulate more than one brain region or more than one network node, rather than targeting a single site. The FOA signals strong interest in technologies that can coordinate stimulation across distributed circuit targets relevant to psychiatric symptoms.
What is closed-loop neuromodulation and why is it important here?
Closed-loop operation means the device integrates sensing and stimulation so it can adjust stimulation based on measured neural or behavioral signals. The FOA emphasizes closed-loop capability as a way to make stimulation more adaptive, precise, and potentially more clinically effective for mental health applications.
Do projects need to be tied to mental health disorders specifically?
Yes. Because this FOA is framed around mental health applications, applicants are expected to explain how the device capabilities connect to psychiatric treatment needs. The FOA indicates applicants should be able to point to plausible targets, biomarkers, or circuit-level hypotheses that justify the proposed engineering direction.
What kinds of teams does NIH expect for a competitive application?
The FOA signals that strong applications are likely to come from multi-disciplinary teams that can cover the device-development pipeline, including:
- Systems neuroscience (to define relevant circuits and signals)
- Engineering (to design and build hardware and software)
- Clinical expertise (to ensure real-world relevance and eventual integration)
- Regulatory affairs expertise (to anticipate safety/testing and future FDA pathway needs)
Why does the FOA highlight regulatory expertise?
The FOA places notable emphasis on regulatory competence because device projects can stall if regulatory planning is not considered early. Incorporating regulatory expertise helps teams anticipate requirements for safety, testing, and potential future FDA pathways.
Is the program limited to academic applicants?
No. The FOA is broadly open to many eligible applicant types, including academic institutions, governments, nonprofits, and for-profit organizations, among others.
Who is eligible to apply (based on the FOA description provided)?
The eligible applicants explicitly include:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits (with or without 501(c)(3) status)
- For-profit organizations (including small businesses)
- Other organizations
Are specific institution types encouraged to apply?
Yes. The FOA highlights additional eligible categories, including:
- Alaska Native and Native Hawaiian Serving Institutions
- AANAPISISs
- Hispanic-serving institutions
- HBCUs
- Tribally Controlled Colleges and Universities
- Faith-based or community-based organizations
- U.S. territories or possessions
- Non-U.S. entities (foreign organizations) and regional organizations
This emphasis underscores an intent to encourage broad participation.
Which federal agency runs this opportunity?
The agency is the National Institutes of Health (NIH).
What is the CFDA number listed for this opportunity?
The CFDA number provided is 93.242.
What is the opportunity number or identifier?
The FOA is identified as PAR 18-941.
When was this opportunity posted and when did it close (based on the provided information)?
The provided posting information indicates a creation date of 2018-09-27 and an original closing date of 2021-09-07.
Is award size or the number of expected awards specified?
No. Based on the information provided, the award ceiling and expected number of awards are not specified.
What stage of work does this opportunity seem to support?
Based on the description provided, the opportunity supports ambitious early-stage device development efforts, including prototype-to-demonstration progress, where the device capability could materially change neuromodulation for mental health (especially via novel modalities, closed-loop designs, multi-target approaches, and substantially improved precision).
Browse more opportunities from the same category: Health
Next opportunity: ImmuneChip: Engineering Microphysiological Immune Tissue Platforms (U01 Clinical Trial Not Allowed)
Previous opportunity: Methodology and Measurement in the Behavioral and Social Sciences (R21) Clinical Trials Optional
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 941
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 941) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional) Apply for PAR 18 942 Funding Number: PAR 18 942 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Leadership Group for an Infectious Diseases Clinical Research Consortium (IDCRC) (UM1 Clinical Trial Required) Apply for RFA AI 18 047 Funding Number: RFA AI 18 047 Agency: National Institutes of Health Category: Health Funding Amount: $1,700,000 |
| Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional) Apply for RFA MH 19 211 Funding Number: RFA MH 19 211 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Voluntary Family Planning for Improved Reproductive Health and Development. Apply for RFI 617 19 FAMILY PLANNING Funding Number: RFI 617 19 FAMILY PLANNING Agency: Uganda USAID-Kampala Category: Health Funding Amount: Case Dependent |
| Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial Required) Apply for RFA AI 18 046 Funding Number: RFA AI 18 046 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Social and Behaviour Change for Transformation (SBC4T) Apply for RFI 617 19 SBC4T Funding Number: RFI 617 19 SBC4T Agency: Uganda USAID-Kampala Category: Health Funding Amount: Case Dependent |
| Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional) Apply for RFA MH 19 210 Funding Number: RFA MH 19 210 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Fc-Dependent Mechanisms of Antibody-Mediated Killing (U01 Clinical Trial Not Allowed) Apply for RFA AI 18 042 Funding Number: RFA AI 18 042 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) Apply for PA 19 020 Funding Number: PA 19 020 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| APS-OAA-16-000001 Addendum Ukraine Health Apply for 72012119RFA00001 Funding Number: 72012119RFA00001 Agency: Ukraine USAID-Kiev Category: Health Funding Amount: $3,000,000 |
| Specialized Alcohol Research Centers Clinical Trial Optional (P50 Clinical Trial Optional) Apply for RFA AA 19 004 Funding Number: RFA AA 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42 Clinical Trial Not Allowed) Apply for PA 19 021 Funding Number: PA 19 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Radiation Biodosimetry Assays and Devices (U01 Clinical Trial Not Allowed) Apply for RFA AI 18 045 Funding Number: RFA AI 18 045 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed) Apply for RFA TW 18 002 Funding Number: RFA TW 18 002 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 022 Funding Number: PA 19 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Basic Neurodevelopmental Biology of Brain Circuits and Behavior (R21 Clinical Trial Not Allowed) Apply for PAR 19 028 Funding Number: PAR 19 028 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed) Apply for PAR 19 027 Funding Number: PAR 19 027 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supp Clinical Trial Optional) Apply for PA 19 031 Funding Number: PA 19 031 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| A Census of Cells and Circuits in the Aging Brain (R01 Clinical Trial Not Allowed) Apply for RFA AG 19 027 Funding Number: RFA AG 19 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Morris K. Udall Center without Walls for Parkinsons Disease Research (P20 Clinical Trial Optional) Apply for RFA NS 18 027 Funding Number: RFA NS 18 027 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 941", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.